Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Esophageal Neoplasms | 57 | 2024 | 127 | 8.380 |
Why?
|
Stomach Neoplasms | 31 | 2023 | 195 | 4.940 |
Why?
|
Opium | 21 | 2024 | 22 | 4.360 |
Why?
|
Iran | 92 | 2024 | 190 | 4.200 |
Why?
|
Carcinoma, Squamous Cell | 30 | 2022 | 178 | 3.870 |
Why?
|
Adenocarcinoma | 27 | 2019 | 251 | 3.230 |
Why?
|
Risk Factors | 101 | 2024 | 3562 | 2.610 |
Why?
|
Cardiovascular Diseases | 21 | 2024 | 664 | 2.540 |
Why?
|
Neoplasms | 23 | 2024 | 1103 | 2.110 |
Why?
|
Cohort Studies | 56 | 2024 | 1492 | 2.050 |
Why?
|
Helicobacter pylori | 12 | 2015 | 109 | 2.000 |
Why?
|
Middle Aged | 127 | 2024 | 10129 | 1.880 |
Why?
|
Humans | 203 | 2024 | 37093 | 1.870 |
Why?
|
Helicobacter Infections | 10 | 2015 | 78 | 1.840 |
Why?
|
Diet | 22 | 2024 | 801 | 1.800 |
Why?
|
Aged | 95 | 2023 | 6741 | 1.720 |
Why?
|
Male | 146 | 2024 | 20025 | 1.680 |
Why?
|
Case-Control Studies | 47 | 2024 | 1130 | 1.640 |
Why?
|
Opioid-Related Disorders | 10 | 2023 | 125 | 1.640 |
Why?
|
Prospective Studies | 42 | 2024 | 1378 | 1.510 |
Why?
|
Female | 137 | 2024 | 20969 | 1.490 |
Why?
|
Drug Users | 3 | 2016 | 46 | 1.460 |
Why?
|
Mortality | 9 | 2021 | 145 | 1.350 |
Why?
|
Carcinogens | 5 | 2020 | 124 | 1.350 |
Why?
|
Adult | 92 | 2024 | 11712 | 1.330 |
Why?
|
Incidence | 34 | 2024 | 922 | 1.260 |
Why?
|
Ilex paraguariensis | 4 | 2018 | 4 | 1.170 |
Why?
|
Registries | 5 | 2021 | 335 | 1.130 |
Why?
|
Environmental Exposure | 9 | 2022 | 216 | 1.110 |
Why?
|
Smoking | 24 | 2022 | 940 | 1.070 |
Why?
|
Opiate Alkaloids | 5 | 2023 | 8 | 1.020 |
Why?
|
Epidemiologic Studies | 4 | 2019 | 31 | 0.950 |
Why?
|
Digestive System Diseases | 2 | 2014 | 4 | 0.950 |
Why?
|
Lung Neoplasms | 6 | 2024 | 358 | 0.940 |
Why?
|
Research Design | 6 | 2018 | 313 | 0.930 |
Why?
|
Proportional Hazards Models | 18 | 2024 | 441 | 0.880 |
Why?
|
Risk Assessment | 18 | 2021 | 753 | 0.860 |
Why?
|
Early Detection of Cancer | 2 | 2017 | 336 | 0.840 |
Why?
|
Odds Ratio | 18 | 2022 | 534 | 0.840 |
Why?
|
Gastroesophageal Reflux | 8 | 2022 | 31 | 0.820 |
Why?
|
Models, Statistical | 3 | 2013 | 180 | 0.820 |
Why?
|
Coronary Stenosis | 1 | 2021 | 34 | 0.790 |
Why?
|
Analgesics, Opioid | 6 | 2023 | 197 | 0.770 |
Why?
|
Cause of Death | 7 | 2023 | 156 | 0.760 |
Why?
|
Coronary Artery Disease | 1 | 2021 | 142 | 0.720 |
Why?
|
Follow-Up Studies | 18 | 2020 | 974 | 0.710 |
Why?
|
Cardia | 5 | 2015 | 5 | 0.700 |
Why?
|
Epidemiologic Methods | 4 | 2013 | 49 | 0.690 |
Why?
|
Tea | 7 | 2019 | 45 | 0.690 |
Why?
|
Colorectal Neoplasms | 7 | 2023 | 441 | 0.680 |
Why?
|
Tooth Loss | 6 | 2024 | 35 | 0.680 |
Why?
|
Adiposity | 2 | 2023 | 154 | 0.660 |
Why?
|
Pepsinogen A | 5 | 2011 | 5 | 0.650 |
Why?
|
Hot Temperature | 6 | 2019 | 128 | 0.640 |
Why?
|
Alcohol Drinking | 11 | 2017 | 519 | 0.640 |
Why?
|
Occult Blood | 1 | 2017 | 29 | 0.610 |
Why?
|
Polymorphism, Genetic | 5 | 2009 | 191 | 0.610 |
Why?
|
Pancreatic Neoplasms | 5 | 2019 | 111 | 0.600 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2024 | 63 | 0.590 |
Why?
|
SEER Program | 1 | 2017 | 91 | 0.590 |
Why?
|
Anticarcinogenic Agents | 2 | 2015 | 65 | 0.590 |
Why?
|
Respiration Disorders | 1 | 2016 | 7 | 0.580 |
Why?
|
Prevalence | 16 | 2023 | 1455 | 0.570 |
Why?
|
Sample Size | 2 | 2013 | 25 | 0.560 |
Why?
|
Risk Reduction Behavior | 2 | 2015 | 127 | 0.560 |
Why?
|
Meat | 6 | 2022 | 43 | 0.550 |
Why?
|
Ghrelin | 4 | 2019 | 13 | 0.530 |
Why?
|
Causality | 2 | 2012 | 44 | 0.510 |
Why?
|
Retrospective Studies | 14 | 2022 | 2026 | 0.510 |
Why?
|
Life Style | 6 | 2021 | 308 | 0.500 |
Why?
|
Aged, 80 and over | 20 | 2021 | 2379 | 0.480 |
Why?
|
Beverages | 3 | 2009 | 68 | 0.480 |
Why?
|
Obesity | 5 | 2023 | 1067 | 0.470 |
Why?
|
Papillomavirus Infections | 4 | 2022 | 336 | 0.470 |
Why?
|
Oral Health | 5 | 2021 | 68 | 0.470 |
Why?
|
Body Mass Index | 10 | 2023 | 854 | 0.460 |
Why?
|
Survival Rate | 7 | 2017 | 311 | 0.460 |
Why?
|
Gastrointestinal Neoplasms | 3 | 2020 | 16 | 0.460 |
Why?
|
Age Factors | 9 | 2021 | 1033 | 0.460 |
Why?
|
Nutritional Sciences | 1 | 2013 | 22 | 0.460 |
Why?
|
Food | 3 | 2023 | 100 | 0.440 |
Why?
|
Pepsinogen C | 2 | 2011 | 2 | 0.440 |
Why?
|
Feeding Behavior | 5 | 2018 | 454 | 0.440 |
Why?
|
Epidemiology | 1 | 2012 | 6 | 0.440 |
Why?
|
Social Class | 7 | 2017 | 247 | 0.430 |
Why?
|
Risk | 7 | 2017 | 267 | 0.430 |
Why?
|
Biomedical Research | 5 | 2023 | 400 | 0.430 |
Why?
|
Surgical Wound Infection | 1 | 2012 | 16 | 0.420 |
Why?
|
Precancerous Conditions | 6 | 2015 | 82 | 0.420 |
Why?
|
Smoking Cessation | 5 | 2023 | 517 | 0.420 |
Why?
|
Hypertension | 5 | 2022 | 796 | 0.420 |
Why?
|
Diet, Mediterranean | 2 | 2023 | 40 | 0.410 |
Why?
|
Antigens, Bacterial | 5 | 2015 | 132 | 0.410 |
Why?
|
Logistic Models | 14 | 2022 | 923 | 0.410 |
Why?
|
China | 9 | 2019 | 196 | 0.400 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2011 | 3 | 0.400 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2022 | 30 | 0.390 |
Why?
|
Venous Thromboembolism | 2 | 2021 | 13 | 0.380 |
Why?
|
alpha-Tocopherol | 5 | 2012 | 27 | 0.380 |
Why?
|
Pepsinogens | 1 | 2010 | 1 | 0.380 |
Why?
|
Colonic Neoplasms | 2 | 2022 | 186 | 0.360 |
Why?
|
Stomach | 1 | 2010 | 45 | 0.360 |
Why?
|
beta Carotene | 4 | 2012 | 11 | 0.360 |
Why?
|
Cardiovascular Agents | 2 | 2020 | 20 | 0.350 |
Why?
|
Esophagogastric Junction | 5 | 2012 | 7 | 0.350 |
Why?
|
Time Factors | 9 | 2021 | 1742 | 0.350 |
Why?
|
Vitamins | 4 | 2015 | 94 | 0.350 |
Why?
|
Antineoplastic Agents | 3 | 2022 | 803 | 0.340 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2012 | 767 | 0.340 |
Why?
|
Sex Factors | 7 | 2021 | 898 | 0.340 |
Why?
|
Skin Diseases | 1 | 2009 | 31 | 0.330 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 121 | 0.330 |
Why?
|
Educational Status | 5 | 2020 | 313 | 0.330 |
Why?
|
Secondary Prevention | 2 | 2019 | 38 | 0.330 |
Why?
|
Drinking | 2 | 2019 | 38 | 0.330 |
Why?
|
Finland | 6 | 2017 | 13 | 0.330 |
Why?
|
Air Pollutants | 2 | 2022 | 94 | 0.320 |
Why?
|
Hepatitis C | 2 | 2020 | 125 | 0.320 |
Why?
|
Glucuronates | 4 | 2013 | 6 | 0.320 |
Why?
|
Tobacco, Smokeless | 4 | 2019 | 18 | 0.320 |
Why?
|
Cross-Sectional Studies | 11 | 2022 | 2721 | 0.320 |
Why?
|
Venous Thrombosis | 2 | 2020 | 28 | 0.320 |
Why?
|
Chemoprevention | 3 | 2007 | 35 | 0.320 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 935 | 0.310 |
Why?
|
Bacterial Proteins | 5 | 2015 | 540 | 0.310 |
Why?
|
Chronic Disease | 6 | 2016 | 484 | 0.310 |
Why?
|
Nuts | 2 | 2018 | 9 | 0.310 |
Why?
|
Oral Hygiene | 2 | 2021 | 17 | 0.300 |
Why?
|
Panax | 1 | 2007 | 7 | 0.300 |
Why?
|
Naphthoquinones | 2 | 2022 | 36 | 0.290 |
Why?
|
Asthma | 1 | 2011 | 380 | 0.290 |
Why?
|
Peer Group | 2 | 2019 | 156 | 0.290 |
Why?
|
Rural Population | 3 | 2013 | 294 | 0.280 |
Why?
|
Nitrosamines | 2 | 2024 | 10 | 0.280 |
Why?
|
Minerals | 3 | 2024 | 47 | 0.280 |
Why?
|
Students | 2 | 2023 | 519 | 0.280 |
Why?
|
Gastritis, Atrophic | 3 | 2011 | 10 | 0.280 |
Why?
|
Volatile Organic Compounds | 2 | 2024 | 17 | 0.280 |
Why?
|
Phytotherapy | 1 | 2007 | 81 | 0.280 |
Why?
|
Waist Circumference | 4 | 2023 | 89 | 0.280 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 182 | 0.280 |
Why?
|
Interleukin-1beta | 1 | 2006 | 70 | 0.280 |
Why?
|
Regression Analysis | 4 | 2017 | 455 | 0.270 |
Why?
|
Epidemiologic Research Design | 2 | 2018 | 16 | 0.270 |
Why?
|
Hepatitis B virus | 1 | 2005 | 13 | 0.260 |
Why?
|
Hepatitis B, Chronic | 1 | 2005 | 10 | 0.260 |
Why?
|
Indomethacin | 1 | 2005 | 28 | 0.260 |
Why?
|
Diet Surveys | 5 | 2019 | 101 | 0.260 |
Why?
|
Papillomaviridae | 4 | 2022 | 127 | 0.260 |
Why?
|
Carrier State | 1 | 2005 | 29 | 0.250 |
Why?
|
Comorbidity | 5 | 2021 | 623 | 0.250 |
Why?
|
Socioeconomic Factors | 7 | 2019 | 1067 | 0.250 |
Why?
|
Reproducibility of Results | 7 | 2021 | 935 | 0.250 |
Why?
|
Antibodies, Viral | 1 | 2006 | 262 | 0.240 |
Why?
|
Diabetes Mellitus | 4 | 2021 | 485 | 0.240 |
Why?
|
Benzo(a)pyrene | 3 | 2012 | 126 | 0.230 |
Why?
|
Food Handling | 2 | 2015 | 33 | 0.230 |
Why?
|
Periodontal Diseases | 2 | 2021 | 49 | 0.230 |
Why?
|
Sensitivity and Specificity | 4 | 2017 | 562 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2010 | 268 | 0.230 |
Why?
|
Environment | 2 | 2019 | 138 | 0.230 |
Why?
|
Alphapapillomavirus | 2 | 2022 | 38 | 0.230 |
Why?
|
Interleukin-1 | 1 | 2003 | 35 | 0.230 |
Why?
|
Trans Fatty Acids | 1 | 2022 | 5 | 0.220 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2023 | 643 | 0.220 |
Why?
|
Virus Replication | 1 | 2005 | 278 | 0.220 |
Why?
|
Carcinoma, Small Cell | 1 | 2022 | 6 | 0.220 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2022 | 4 | 0.220 |
Why?
|
Heart Diseases | 2 | 2015 | 104 | 0.210 |
Why?
|
Cheese | 1 | 2022 | 3 | 0.210 |
Why?
|
Drug Combinations | 2 | 2020 | 98 | 0.210 |
Why?
|
Pyrenes | 4 | 2013 | 25 | 0.210 |
Why?
|
Coffee | 2 | 2015 | 20 | 0.210 |
Why?
|
Intensive Care Units | 1 | 2022 | 59 | 0.210 |
Why?
|
Gastric Mucosa | 2 | 2015 | 51 | 0.210 |
Why?
|
Amino Alcohols | 1 | 2022 | 1 | 0.210 |
Why?
|
Occupational Diseases | 1 | 2022 | 47 | 0.210 |
Why?
|
Dyspepsia | 2 | 2012 | 5 | 0.210 |
Why?
|
Lead Poisoning | 1 | 2022 | 26 | 0.200 |
Why?
|
Occupational Exposure | 1 | 2022 | 79 | 0.200 |
Why?
|
Vegetables | 3 | 2015 | 147 | 0.200 |
Why?
|
Air Pollution | 1 | 2022 | 60 | 0.200 |
Why?
|
Dairy Products | 2 | 2022 | 35 | 0.200 |
Why?
|
Mutation | 2 | 2020 | 1095 | 0.200 |
Why?
|
Head and Neck Neoplasms | 1 | 2022 | 78 | 0.200 |
Why?
|
Multivariate Analysis | 6 | 2019 | 583 | 0.200 |
Why?
|
Postoperative Complications | 2 | 2017 | 210 | 0.200 |
Why?
|
Asparaginase | 1 | 2021 | 4 | 0.200 |
Why?
|
Nails | 2 | 2018 | 5 | 0.200 |
Why?
|
Coronary Angiography | 1 | 2021 | 90 | 0.200 |
Why?
|
Mouth | 1 | 2021 | 45 | 0.200 |
Why?
|
Dietary Supplements | 3 | 2009 | 208 | 0.190 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2019 | 62 | 0.190 |
Why?
|
Inflammation | 1 | 2006 | 618 | 0.190 |
Why?
|
Brucellosis | 1 | 2020 | 8 | 0.190 |
Why?
|
Q Fever | 1 | 2020 | 7 | 0.190 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 39 | 0.190 |
Why?
|
ROC Curve | 3 | 2017 | 138 | 0.190 |
Why?
|
Coxiella burnetii | 1 | 2020 | 16 | 0.190 |
Why?
|
Myocardial Ischemia | 2 | 2018 | 75 | 0.190 |
Why?
|
Household Articles | 1 | 2020 | 2 | 0.190 |
Why?
|
Double-Blind Method | 5 | 2012 | 286 | 0.190 |
Why?
|
Genetic Predisposition to Disease | 4 | 2009 | 628 | 0.190 |
Why?
|
Government Programs | 1 | 2020 | 29 | 0.190 |
Why?
|
Plant Leaves | 2 | 2018 | 124 | 0.190 |
Why?
|
Selenium | 4 | 2017 | 148 | 0.180 |
Why?
|
Pulmonary Embolism | 1 | 2020 | 32 | 0.180 |
Why?
|
Patient Discharge | 1 | 2020 | 93 | 0.180 |
Why?
|
Antioxidants | 4 | 2015 | 416 | 0.180 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2020 | 19 | 0.180 |
Why?
|
Substance-Related Disorders | 2 | 2018 | 730 | 0.180 |
Why?
|
Sulfonamides | 1 | 2020 | 80 | 0.180 |
Why?
|
Flavonoids | 1 | 2020 | 87 | 0.180 |
Why?
|
Developing Countries | 3 | 2018 | 99 | 0.180 |
Why?
|
Cholecystectomy | 2 | 2017 | 7 | 0.180 |
Why?
|
Mouth Mucosa | 1 | 2019 | 34 | 0.180 |
Why?
|
Primary Health Care | 2 | 2020 | 294 | 0.170 |
Why?
|
Telomerase | 1 | 2020 | 44 | 0.170 |
Why?
|
History of Medicine | 1 | 2019 | 1 | 0.170 |
Why?
|
Genetic Testing | 1 | 2020 | 75 | 0.170 |
Why?
|
Waist-Hip Ratio | 1 | 2019 | 34 | 0.170 |
Why?
|
Family Characteristics | 1 | 2020 | 108 | 0.170 |
Why?
|
Fruit | 2 | 2015 | 173 | 0.170 |
Why?
|
DNA, Viral | 4 | 2010 | 304 | 0.170 |
Why?
|
Substance Abuse, Intravenous | 1 | 2020 | 121 | 0.170 |
Why?
|
Cultural Diversity | 1 | 2020 | 169 | 0.170 |
Why?
|
Biopsy | 4 | 2013 | 164 | 0.170 |
Why?
|
United States | 7 | 2023 | 4223 | 0.170 |
Why?
|
Intra-Abdominal Fat | 1 | 2019 | 45 | 0.170 |
Why?
|
Medically Underserved Area | 1 | 2019 | 104 | 0.160 |
Why?
|
Pancreatic Fistula | 1 | 2018 | 2 | 0.160 |
Why?
|
Pancreatectomy | 1 | 2018 | 3 | 0.160 |
Why?
|
Antihypertensive Agents | 2 | 2019 | 284 | 0.160 |
Why?
|
Carcinoma | 1 | 2019 | 96 | 0.160 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2022 | 1039 | 0.160 |
Why?
|
Hospitalization | 2 | 2022 | 388 | 0.160 |
Why?
|
Bacteria | 1 | 2021 | 255 | 0.160 |
Why?
|
Accidents, Traffic | 1 | 2018 | 42 | 0.160 |
Why?
|
Genotype | 4 | 2012 | 730 | 0.160 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2018 | 52 | 0.160 |
Why?
|
Escherichia coli | 1 | 2021 | 453 | 0.150 |
Why?
|
Stroke | 2 | 2018 | 286 | 0.150 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 69 | 0.150 |
Why?
|
Animals | 9 | 2022 | 15081 | 0.150 |
Why?
|
Antiviral Agents | 1 | 2019 | 157 | 0.150 |
Why?
|
Treatment Outcome | 5 | 2014 | 1369 | 0.150 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 77 | 0.150 |
Why?
|
Sex Characteristics | 2 | 2017 | 230 | 0.150 |
Why?
|
Colonoscopy | 1 | 2017 | 104 | 0.150 |
Why?
|
Torsades de Pointes | 1 | 2016 | 2 | 0.150 |
Why?
|
Constipation | 1 | 2016 | 5 | 0.150 |
Why?
|
Dietary Proteins | 1 | 2017 | 32 | 0.150 |
Why?
|
Prognosis | 6 | 2019 | 739 | 0.150 |
Why?
|
Endocrine System Diseases | 1 | 2016 | 13 | 0.150 |
Why?
|
Universities | 1 | 2020 | 442 | 0.140 |
Why?
|
Intraoperative Complications | 1 | 2017 | 18 | 0.140 |
Why?
|
Community-Based Participatory Research | 2 | 2019 | 317 | 0.140 |
Why?
|
Hypotension | 1 | 2016 | 23 | 0.140 |
Why?
|
Immune System Diseases | 1 | 2016 | 21 | 0.140 |
Why?
|
Body Size | 2 | 2014 | 32 | 0.140 |
Why?
|
Fuel Oils | 1 | 2016 | 1 | 0.140 |
Why?
|
Verbal Behavior | 1 | 2016 | 13 | 0.140 |
Why?
|
MAP Kinase Kinase 4 | 2 | 2006 | 31 | 0.140 |
Why?
|
Food Preferences | 1 | 2017 | 73 | 0.140 |
Why?
|
Wounds and Injuries | 1 | 2017 | 161 | 0.140 |
Why?
|
Ethanol | 1 | 2018 | 192 | 0.130 |
Why?
|
Neoplasm Proteins | 2 | 2009 | 213 | 0.130 |
Why?
|
Mass Screening | 2 | 2017 | 462 | 0.130 |
Why?
|
Young Adult | 8 | 2021 | 4268 | 0.130 |
Why?
|
Ruminants | 3 | 2022 | 7 | 0.130 |
Why?
|
Counseling | 1 | 2016 | 116 | 0.130 |
Why?
|
Adolescent | 8 | 2021 | 5363 | 0.130 |
Why?
|
HIV Infections | 2 | 2020 | 2303 | 0.130 |
Why?
|
Aggression | 1 | 2016 | 89 | 0.130 |
Why?
|
Size Perception | 1 | 2015 | 5 | 0.130 |
Why?
|
Trace Elements | 1 | 2015 | 30 | 0.130 |
Why?
|
ABO Blood-Group System | 1 | 2015 | 5 | 0.130 |
Why?
|
Chi-Square Distribution | 4 | 2012 | 225 | 0.130 |
Why?
|
Catheterization, Central Venous | 1 | 2015 | 6 | 0.130 |
Why?
|
Sex Distribution | 6 | 2015 | 215 | 0.130 |
Why?
|
History, Ancient | 3 | 2020 | 12 | 0.130 |
Why?
|
Systole | 1 | 2015 | 61 | 0.130 |
Why?
|
Hemorrhage | 1 | 2015 | 45 | 0.120 |
Why?
|
Kidney Failure, Chronic | 1 | 2017 | 233 | 0.120 |
Why?
|
Neoplasm Staging | 5 | 2016 | 275 | 0.120 |
Why?
|
Sodium Chloride, Dietary | 1 | 2015 | 41 | 0.120 |
Why?
|
Animal Husbandry | 1 | 2014 | 18 | 0.120 |
Why?
|
Leukemia | 1 | 2015 | 56 | 0.120 |
Why?
|
Gallbladder | 1 | 2014 | 3 | 0.120 |
Why?
|
Cholecystitis | 1 | 2014 | 5 | 0.120 |
Why?
|
Barrett Esophagus | 2 | 2015 | 31 | 0.120 |
Why?
|
Seroepidemiologic Studies | 2 | 2020 | 68 | 0.120 |
Why?
|
Anticoagulants | 1 | 2015 | 102 | 0.120 |
Why?
|
Laparoscopes | 1 | 2013 | 1 | 0.120 |
Why?
|
Hernia, Ventral | 1 | 2013 | 3 | 0.120 |
Why?
|
Gallbladder Diseases | 1 | 2013 | 3 | 0.120 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 2013 | 7 | 0.120 |
Why?
|
Health Surveys | 2 | 2014 | 373 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2015 | 128 | 0.120 |
Why?
|
Decision Support Techniques | 1 | 2014 | 47 | 0.120 |
Why?
|
Delivery of Health Care | 3 | 2013 | 276 | 0.120 |
Why?
|
Phenotype | 2 | 2015 | 689 | 0.120 |
Why?
|
Parturition | 1 | 2013 | 24 | 0.120 |
Why?
|
Portal Vein | 1 | 2013 | 4 | 0.120 |
Why?
|
Pneumatosis Cystoides Intestinalis | 1 | 2013 | 2 | 0.120 |
Why?
|
Reproductive History | 1 | 2013 | 19 | 0.110 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 448 | 0.110 |
Why?
|
Nutritional Status | 2 | 2017 | 116 | 0.110 |
Why?
|
Hematocrit | 1 | 2013 | 18 | 0.110 |
Why?
|
Awareness | 1 | 2013 | 65 | 0.110 |
Why?
|
Philosophy | 1 | 2012 | 2 | 0.110 |
Why?
|
DNA Adducts | 1 | 2012 | 42 | 0.110 |
Why?
|
Asia | 3 | 2009 | 75 | 0.110 |
Why?
|
Receptors, Estrogen | 1 | 2013 | 156 | 0.110 |
Why?
|
Food, Preserved | 1 | 2012 | 2 | 0.110 |
Why?
|
Predictive Value of Tests | 4 | 2017 | 400 | 0.100 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 111 | 0.100 |
Why?
|
Statistics as Topic | 1 | 2012 | 117 | 0.100 |
Why?
|
Urban Population | 3 | 2013 | 333 | 0.100 |
Why?
|
Gastric Fundus | 1 | 2011 | 3 | 0.100 |
Why?
|
Patient Selection | 1 | 2013 | 164 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 1 | 2013 | 214 | 0.100 |
Why?
|
Gastritis | 1 | 2011 | 11 | 0.100 |
Why?
|
Religion | 1 | 2012 | 87 | 0.100 |
Why?
|
Genes, p53 | 1 | 2011 | 25 | 0.100 |
Why?
|
Gastrins | 1 | 2011 | 9 | 0.100 |
Why?
|
Purpura, Thrombocytopenic, Idiopathic | 1 | 2011 | 4 | 0.100 |
Why?
|
Peptic Ulcer | 1 | 2011 | 9 | 0.100 |
Why?
|
Software | 1 | 2013 | 217 | 0.100 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2011 | 18 | 0.100 |
Why?
|
DNA Repair | 1 | 2012 | 188 | 0.100 |
Why?
|
Motor Activity | 1 | 2014 | 418 | 0.100 |
Why?
|
Iron | 1 | 2012 | 225 | 0.090 |
Why?
|
Autopsy | 1 | 2010 | 43 | 0.090 |
Why?
|
Atrophy | 1 | 2010 | 42 | 0.090 |
Why?
|
Health Care Reform | 1 | 2010 | 32 | 0.090 |
Why?
|
Cost of Illness | 2 | 2011 | 76 | 0.090 |
Why?
|
Proton Pump Inhibitors | 1 | 2009 | 9 | 0.090 |
Why?
|
Quality-Adjusted Life Years | 2 | 2019 | 44 | 0.090 |
Why?
|
Plant Extracts | 1 | 2012 | 286 | 0.090 |
Why?
|
Confidence Intervals | 4 | 2011 | 149 | 0.090 |
Why?
|
Mucous Membrane | 1 | 2009 | 34 | 0.090 |
Why?
|
Copper | 2 | 2024 | 105 | 0.090 |
Why?
|
Air Pollution, Indoor | 2 | 2020 | 41 | 0.080 |
Why?
|
Diet Records | 2 | 2021 | 60 | 0.080 |
Why?
|
History, 19th Century | 2 | 2020 | 24 | 0.080 |
Why?
|
Tocopherols | 1 | 2009 | 65 | 0.080 |
Why?
|
Models, Biological | 1 | 2012 | 677 | 0.080 |
Why?
|
Micronutrients | 1 | 2009 | 44 | 0.080 |
Why?
|
History, 21st Century | 2 | 2020 | 81 | 0.080 |
Why?
|
Pilot Projects | 3 | 2009 | 661 | 0.080 |
Why?
|
History, 20th Century | 2 | 2020 | 117 | 0.080 |
Why?
|
Public Health | 1 | 2012 | 372 | 0.080 |
Why?
|
Acute Disease | 2 | 2021 | 147 | 0.080 |
Why?
|
Minority Groups | 2 | 2023 | 596 | 0.080 |
Why?
|
Biodiversity | 2 | 2021 | 83 | 0.080 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2008 | 81 | 0.080 |
Why?
|
Cell Line, Tumor | 3 | 2022 | 2231 | 0.080 |
Why?
|
Ferritins | 2 | 2022 | 55 | 0.080 |
Why?
|
Baltimore | 2 | 2020 | 52 | 0.080 |
Why?
|
Food Contamination | 1 | 2008 | 55 | 0.080 |
Why?
|
Bile Duct Neoplasms | 1 | 2007 | 3 | 0.080 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2007 | 4 | 0.080 |
Why?
|
Cholangiocarcinoma | 1 | 2007 | 6 | 0.070 |
Why?
|
Americas | 1 | 2006 | 7 | 0.070 |
Why?
|
Goiter | 1 | 2006 | 1 | 0.070 |
Why?
|
Developed Countries | 1 | 2006 | 12 | 0.070 |
Why?
|
Blood Pressure | 2 | 2022 | 646 | 0.070 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2006 | 14 | 0.070 |
Why?
|
Europe | 1 | 2006 | 101 | 0.070 |
Why?
|
Cytochrome P-450 CYP1A2 | 1 | 2006 | 28 | 0.070 |
Why?
|
Glucuronosyltransferase | 1 | 2006 | 25 | 0.070 |
Why?
|
Antibodies, Bacterial | 2 | 2020 | 109 | 0.070 |
Why?
|
Primary Prevention | 1 | 2006 | 59 | 0.070 |
Why?
|
Exonucleases | 1 | 2006 | 3 | 0.070 |
Why?
|
Glutathione Transferase | 1 | 2006 | 88 | 0.070 |
Why?
|
Cytochrome P-450 CYP1A1 | 1 | 2006 | 51 | 0.070 |
Why?
|
Receptors, Interleukin | 1 | 2006 | 11 | 0.070 |
Why?
|
Carcinogens, Environmental | 1 | 2006 | 35 | 0.070 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 1 | 2006 | 52 | 0.070 |
Why?
|
Interleukins | 1 | 2006 | 29 | 0.070 |
Why?
|
Receptors, Aryl Hydrocarbon | 1 | 2006 | 48 | 0.070 |
Why?
|
Smoke | 1 | 2006 | 40 | 0.070 |
Why?
|
Tobacco Smoke Pollution | 1 | 2006 | 48 | 0.070 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2020 | 88 | 0.070 |
Why?
|
Gastrectomy | 1 | 2005 | 10 | 0.070 |
Why?
|
Hepatitis B e Antigens | 1 | 2005 | 1 | 0.070 |
Why?
|
Water Pollutants, Chemical | 1 | 2008 | 164 | 0.070 |
Why?
|
Hepatitis B Antibodies | 1 | 2005 | 6 | 0.060 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2005 | 11 | 0.060 |
Why?
|
Liver Function Tests | 1 | 2005 | 18 | 0.060 |
Why?
|
Haplotypes | 1 | 2006 | 182 | 0.060 |
Why?
|
Water Supply | 2 | 2019 | 57 | 0.060 |
Why?
|
Liver Neoplasms | 1 | 2007 | 190 | 0.060 |
Why?
|
Brazil | 3 | 2012 | 64 | 0.060 |
Why?
|
Age Distribution | 4 | 2005 | 225 | 0.060 |
Why?
|
Body Weights and Measures | 2 | 2018 | 22 | 0.060 |
Why?
|
Genetics, Population | 1 | 2004 | 100 | 0.060 |
Why?
|
Toothbrushing | 1 | 2024 | 8 | 0.060 |
Why?
|
Self Disclosure | 1 | 2004 | 42 | 0.060 |
Why?
|
Mouth Neoplasms | 1 | 2005 | 71 | 0.060 |
Why?
|
Fat Necrosis | 1 | 2003 | 3 | 0.060 |
Why?
|
Hepatitis | 1 | 2003 | 9 | 0.060 |
Why?
|
Maryland | 2 | 2019 | 53 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2006 | 356 | 0.060 |
Why?
|
Entrepreneurship | 1 | 2023 | 5 | 0.060 |
Why?
|
Rural Health | 2 | 2019 | 53 | 0.060 |
Why?
|
Heartburn | 1 | 2022 | 2 | 0.060 |
Why?
|
Fatty Liver | 1 | 2003 | 64 | 0.050 |
Why?
|
Plant Oils | 1 | 2022 | 18 | 0.050 |
Why?
|
Occupations | 1 | 2022 | 23 | 0.050 |
Why?
|
Yogurt | 1 | 2022 | 4 | 0.050 |
Why?
|
Troponin | 1 | 2022 | 15 | 0.050 |
Why?
|
Substance Abuse Detection | 2 | 2017 | 30 | 0.050 |
Why?
|
Milk | 1 | 2022 | 50 | 0.050 |
Why?
|
Membrane Proteins | 1 | 2006 | 517 | 0.050 |
Why?
|
Particulate Matter | 1 | 2022 | 51 | 0.050 |
Why?
|
Radioimmunoassay | 2 | 2011 | 65 | 0.050 |
Why?
|
Diarrhea | 1 | 2022 | 89 | 0.050 |
Why?
|
Microsomes, Liver | 1 | 2022 | 70 | 0.050 |
Why?
|
Health Education | 2 | 2018 | 338 | 0.050 |
Why?
|
Acids | 1 | 2021 | 18 | 0.050 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2022 | 113 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2006 | 560 | 0.050 |
Why?
|
Reference Values | 2 | 2011 | 212 | 0.050 |
Why?
|
Antithrombin III | 1 | 2021 | 4 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2014 | 610 | 0.050 |
Why?
|
Linear Models | 3 | 2009 | 275 | 0.050 |
Why?
|
U937 Cells | 1 | 2020 | 27 | 0.050 |
Why?
|
K562 Cells | 1 | 2020 | 32 | 0.050 |
Why?
|
Lead | 1 | 2022 | 93 | 0.050 |
Why?
|
HL-60 Cells | 1 | 2020 | 32 | 0.050 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 45 | 0.050 |
Why?
|
Calcium | 1 | 2024 | 480 | 0.050 |
Why?
|
Kerosene | 1 | 2020 | 1 | 0.050 |
Why?
|
Overweight | 1 | 2023 | 247 | 0.050 |
Why?
|
Heating | 1 | 2020 | 4 | 0.050 |
Why?
|
Liver | 1 | 2003 | 479 | 0.050 |
Why?
|
Structure-Activity Relationship | 1 | 2022 | 409 | 0.050 |
Why?
|
Wood | 1 | 2020 | 16 | 0.050 |
Why?
|
Breast Neoplasms | 1 | 2011 | 1502 | 0.050 |
Why?
|
Mice | 2 | 2022 | 5913 | 0.050 |
Why?
|
Biomass | 1 | 2020 | 54 | 0.050 |
Why?
|
Alleles | 2 | 2012 | 321 | 0.050 |
Why?
|
Hepacivirus | 1 | 2020 | 62 | 0.050 |
Why?
|
Population Surveillance | 2 | 2014 | 238 | 0.050 |
Why?
|
Chromatography, Affinity | 2 | 2013 | 67 | 0.040 |
Why?
|
Molecular Structure | 1 | 2022 | 492 | 0.040 |
Why?
|
Tretinoin | 1 | 2020 | 50 | 0.040 |
Why?
|
B-Lymphocytes | 1 | 2021 | 185 | 0.040 |
Why?
|
Early Diagnosis | 1 | 2020 | 64 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 152 | 0.040 |
Why?
|
Enalapril | 1 | 2019 | 7 | 0.040 |
Why?
|
Placebos | 2 | 2012 | 37 | 0.040 |
Why?
|
Hydrochlorothiazide | 1 | 2019 | 19 | 0.040 |
Why?
|
Income | 1 | 2020 | 140 | 0.040 |
Why?
|
Persia | 1 | 2019 | 1 | 0.040 |
Why?
|
Anticholesteremic Agents | 1 | 2019 | 23 | 0.040 |
Why?
|
Health Transition | 1 | 2019 | 4 | 0.040 |
Why?
|
Cholesterol, LDL | 1 | 2019 | 68 | 0.040 |
Why?
|
Immunohistochemistry | 3 | 2006 | 893 | 0.040 |
Why?
|
Middle East | 1 | 2019 | 18 | 0.040 |
Why?
|
Administration, Oral | 1 | 2020 | 224 | 0.040 |
Why?
|
Aspirin | 1 | 2019 | 49 | 0.040 |
Why?
|
Eating | 1 | 2020 | 166 | 0.040 |
Why?
|
Health Behavior | 2 | 2016 | 537 | 0.040 |
Why?
|
Disabled Persons | 1 | 2019 | 65 | 0.040 |
Why?
|
Malnutrition | 2 | 2009 | 44 | 0.040 |
Why?
|
Octreotide | 1 | 2018 | 2 | 0.040 |
Why?
|
Pancreaticoduodenectomy | 1 | 2018 | 3 | 0.040 |
Why?
|
Gastrointestinal Agents | 1 | 2018 | 5 | 0.040 |
Why?
|
Exercise | 2 | 2017 | 613 | 0.040 |
Why?
|
Alkaloids | 1 | 2019 | 39 | 0.040 |
Why?
|
Urban Health | 1 | 2019 | 95 | 0.040 |
Why?
|
Cell Survival | 1 | 2022 | 864 | 0.040 |
Why?
|
Hematologic Tests | 1 | 2018 | 7 | 0.040 |
Why?
|
Hair | 1 | 2018 | 20 | 0.040 |
Why?
|
Urinalysis | 1 | 2018 | 30 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2021 | 357 | 0.040 |
Why?
|
Scandium | 1 | 2017 | 2 | 0.040 |
Why?
|
Temperature | 1 | 2019 | 286 | 0.040 |
Why?
|
Chromium | 1 | 2017 | 27 | 0.040 |
Why?
|
Residence Characteristics | 2 | 2012 | 322 | 0.040 |
Why?
|
Mercury | 1 | 2017 | 39 | 0.040 |
Why?
|
Promoter Regions, Genetic | 1 | 2020 | 515 | 0.040 |
Why?
|
Marriage | 1 | 2017 | 16 | 0.040 |
Why?
|
Poultry Products | 1 | 2017 | 1 | 0.040 |
Why?
|
Eggs | 1 | 2017 | 7 | 0.040 |
Why?
|
Medication Adherence | 1 | 2019 | 179 | 0.040 |
Why?
|
Postoperative Period | 1 | 2017 | 27 | 0.040 |
Why?
|
History, 15th Century | 1 | 2016 | 1 | 0.040 |
Why?
|
History, Medieval | 1 | 2016 | 4 | 0.040 |
Why?
|
History, 16th Century | 1 | 2016 | 5 | 0.040 |
Why?
|
History, 17th Century | 1 | 2016 | 5 | 0.040 |
Why?
|
History, 18th Century | 1 | 2016 | 6 | 0.040 |
Why?
|
Drug Tolerance | 1 | 2016 | 40 | 0.040 |
Why?
|
Fabaceae | 1 | 2017 | 27 | 0.040 |
Why?
|
Endosonography | 1 | 2016 | 3 | 0.040 |
Why?
|
Zinc | 1 | 2017 | 128 | 0.040 |
Why?
|
Medical Staff, Hospital | 1 | 2016 | 13 | 0.030 |
Why?
|
Cooperative Behavior | 1 | 2018 | 219 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2022 | 1198 | 0.030 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 55 | 0.030 |
Why?
|
Nitrate Reductase | 1 | 2015 | 2 | 0.030 |
Why?
|
Chaperonin 60 | 1 | 2015 | 18 | 0.030 |
Why?
|
Databases, Factual | 1 | 2017 | 291 | 0.030 |
Why?
|
Age of Onset | 1 | 2015 | 100 | 0.030 |
Why?
|
Serologic Tests | 1 | 2015 | 43 | 0.030 |
Why?
|
Nonlinear Dynamics | 1 | 2015 | 33 | 0.030 |
Why?
|
von Willebrand Factor | 1 | 2015 | 5 | 0.030 |
Why?
|
Factor VIII | 1 | 2015 | 11 | 0.030 |
Why?
|
Metagenome | 1 | 2015 | 29 | 0.030 |
Why?
|
Magnesium | 1 | 2015 | 97 | 0.030 |
Why?
|
Internship and Residency | 1 | 2016 | 125 | 0.030 |
Why?
|
Anthropometry | 1 | 2015 | 97 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2020 | 458 | 0.030 |
Why?
|
Gangrene | 1 | 2014 | 2 | 0.030 |
Why?
|
Cholecystitis, Acute | 1 | 2014 | 3 | 0.030 |
Why?
|
Survival Analysis | 2 | 2005 | 325 | 0.030 |
Why?
|
Stillbirth | 1 | 2013 | 10 | 0.030 |
Why?
|
Self Concept | 1 | 2015 | 154 | 0.030 |
Why?
|
Parity | 1 | 2013 | 46 | 0.030 |
Why?
|
Preoperative Care | 1 | 2013 | 26 | 0.030 |
Why?
|
Dentition | 1 | 2013 | 1 | 0.030 |
Why?
|
Abortion, Spontaneous | 1 | 2013 | 24 | 0.030 |
Why?
|
Necrosis | 1 | 2013 | 49 | 0.030 |
Why?
|
Geography | 1 | 2013 | 96 | 0.030 |
Why?
|
Ischemia | 1 | 2013 | 46 | 0.030 |
Why?
|
Mastication | 1 | 2012 | 19 | 0.030 |
Why?
|
Gastroscopy | 1 | 2012 | 7 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2015 | 222 | 0.030 |
Why?
|
Transferrin | 1 | 2012 | 40 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 108 | 0.030 |
Why?
|
Codon | 1 | 2011 | 42 | 0.030 |
Why?
|
Cell Growth Processes | 1 | 2011 | 41 | 0.030 |
Why?
|
Area Under Curve | 1 | 2011 | 88 | 0.030 |
Why?
|
Australia | 1 | 2011 | 76 | 0.030 |
Why?
|
Canada | 1 | 2011 | 130 | 0.020 |
Why?
|
Hospitals | 1 | 2012 | 86 | 0.020 |
Why?
|
Health Policy | 1 | 2013 | 165 | 0.020 |
Why?
|
Inpatients | 1 | 2012 | 74 | 0.020 |
Why?
|
Demography | 1 | 2011 | 175 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2012 | 550 | 0.020 |
Why?
|
Health Care Costs | 1 | 2011 | 77 | 0.020 |
Why?
|
Morbidity | 1 | 2010 | 91 | 0.020 |
Why?
|
DNA Modification Methylases | 1 | 2009 | 4 | 0.020 |
Why?
|
Turkmenistan | 1 | 2009 | 1 | 0.020 |
Why?
|
Alcohol Dehydrogenase | 1 | 2009 | 10 | 0.020 |
Why?
|
DNA Repair Enzymes | 1 | 2009 | 20 | 0.020 |
Why?
|
gamma-Tocopherol | 1 | 2009 | 19 | 0.020 |
Why?
|
Molybdenum | 1 | 2009 | 14 | 0.020 |
Why?
|
Riboflavin | 1 | 2009 | 24 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2010 | 502 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2010 | 173 | 0.020 |
Why?
|
Zinc Oxide | 1 | 2009 | 16 | 0.020 |
Why?
|
Niacin | 1 | 2009 | 22 | 0.020 |
Why?
|
Ascorbic Acid | 1 | 2009 | 66 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2011 | 461 | 0.020 |
Why?
|
Physical Examination | 1 | 2008 | 43 | 0.020 |
Why?
|
Vitamin A | 1 | 2009 | 87 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 448 | 0.020 |
Why?
|
Diterpenes | 1 | 2009 | 92 | 0.020 |
Why?
|
Nutrition Policy | 1 | 2009 | 70 | 0.020 |
Why?
|
Pregnancy | 1 | 2013 | 1549 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2009 | 194 | 0.020 |
Why?
|
Antibodies, Neoplasm | 1 | 2007 | 16 | 0.020 |
Why?
|
Disease Progression | 1 | 2009 | 601 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2007 | 227 | 0.020 |
Why?
|
Cocarcinogenesis | 1 | 2006 | 7 | 0.020 |
Why?
|
Genes, Tumor Suppressor | 1 | 2006 | 63 | 0.020 |
Why?
|
Biotransformation | 1 | 2006 | 67 | 0.020 |
Why?
|
Exoribonucleases | 1 | 2006 | 8 | 0.020 |
Why?
|
Cotinine | 1 | 2006 | 43 | 0.020 |
Why?
|
14-3-3 Proteins | 1 | 2006 | 22 | 0.020 |
Why?
|
Metaplasia | 1 | 2006 | 37 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2006 | 67 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2006 | 61 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2006 | 168 | 0.020 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2008 | 421 | 0.020 |
Why?
|
Oxidative Stress | 1 | 2011 | 938 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2005 | 60 | 0.020 |
Why?
|
Hospitals, University | 1 | 2005 | 38 | 0.020 |
Why?
|
Probability | 1 | 2005 | 78 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2005 | 113 | 0.020 |
Why?
|
Ecology | 1 | 2004 | 22 | 0.020 |
Why?
|
Enzymes | 1 | 2004 | 32 | 0.020 |
Why?
|
Codeine | 1 | 2004 | 1 | 0.020 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2004 | 2 | 0.020 |
Why?
|
Hypertriglyceridemia | 1 | 2003 | 14 | 0.010 |
Why?
|
Morphine | 1 | 2004 | 85 | 0.010 |
Why?
|
Hyperlipidemias | 1 | 2003 | 36 | 0.010 |
Why?
|
Liver Cirrhosis | 1 | 2003 | 52 | 0.010 |
Why?
|
Gene Expression | 1 | 2006 | 674 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2003 | 184 | 0.010 |
Why?
|